Key result
Acute withdrawal of pravastatin after 6 weeks of therapy in healthy volunteers significantly reduced evoked cerebral flow velocity responses compared to baseline (11% vs 13%; P<0.01).
Why the study?
Does initiation and acute withdrawal of pravastatin affect resting and functionally activated cerebral hemodynamics in healthy young volunteers?
RCT (n=16)
Double-blind
Does initiation and acute withdrawal of pravastatin affect resting and functionally activated cerebral hemodynamics in healthy young volunteers?
Absolute Event Rate: 11% vs 13%
p-value: p=<0.01
Acute withdrawal of statin therapy in healthy volunteers significantly reduces evoked cerebral flow velocity responses, suggesting impaired neurovascular coupling and reduced nitric oxide bioavailability.
Acute statin withdrawal impairs cerebral vasoreactivity in healthy volunteers; extends RCT evidence for pleiotropic effects and supports caution with abrupt discontinuation.
BACKGROUND AND PURPOSE: Recent clinical trials imply increased risk of vascular events after statin withdrawal. There is evidence that this observation relates to an impaired nitric oxide system. The present analysis investigates the effect of initiation and withdrawal of statin therapy on resting and functionally activated cerebral hemodynamics in healthy young volunteers. METHODS: Sixteen healthy students (aged 23.7+/-3.3 years, 10 male) were subjected to a placebo-controlled, double-blind crossover study with a washout phase between blocks of 4 weeks. In the verum group, 20 mg pravastatin was taken for 2 weeks followed by 40 mg for 4 weeks. Withdrawal effects were investigated the day after discontinuation. Total cholesterol levels, blood pressure, resting and evoked hemodynamic responses due to a visual stimulation task in the posterior cerebral artery were obtained at baseline and then weekly and the day after discontinuation. RESULTS: In the verum group, cholesterol levels significantly decreased after 2 weeks (from 183+/-30 to 150+/-28 mg/dL; P<0.001) and then remained nearly stable (147+/-21 mg/dL after 6 weeks). Blood pressure, resting and evoked hemodynamic responses remained constant throughout the study. The day after statin withdrawal, evoked flow velocity responses were significantly lower (11+/-4% versus 13+/-5% at baseline; P<0.01) indicating inappropriate blood supply of active neurons. CONCLUSIONS: Reduction in evoked flow velocity responses reflects reduced nitric oxide bioavailability and therefore supports molecular findings of acute statin withdrawal. Questions arise if the present data might give a link to reports of increased vascular events in patients at vascular risk after acute statin withdrawal.
No takes yet. Share an insight, caveat, or question.
Rosengarten et al. (2007) conducted an RCT in Healthy, normocholesterolemic (n=16). Pravastatin vs. Placebo / Baseline was evaluated on Evoked flow velocity responses the day after statin withdrawal (p=<0.01). Acute withdrawal of pravastatin after 6 weeks of therapy in healthy volunteers significantly reduced evoked cerebral flow velocity responses compared to baseline (11% vs 13%; P<0.01).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: